1	LYNBROOK	lynbrook	NNP	_	5	nn	_
2	,	,	,	_	1	punct	_
3	N.Y.	n.y.	NNP	_	1	appos	_
4	,	,	,	_	1	punct	_
5	May	may	NNP	_	15	nn	_
6	19	0	CD	_	5	num	_
7	,	,	,	_	8	punct	_
8	2014	0	CD	_	15	num	_
9	/	/	SYM	p2=,	5	punct	_
10	PRNewswire	prnewswire	NNP	p2=NN	0	root	_
11	/	/	SYM	p2=NNPS	15	punct	_
12	--	--	:	p2=.	10	punct	_
13	 BioSpecifics	 biospecifics	NNS	p2=NNP	15	nn	_
14	Technologies	technology	NNPS	p2=VBZ	15	nn	_
15	Corp	corp	NNP	_	10	appos	_
16	.	.	.	_	10	punct	_

1	(	(	-LRB-	_	2	punct	_
2	BSTC	bstc	NNP	_	36	nsubj	36:A0=PAG
3	)	)	-RRB-	_	2	punct	_
4	,	,	,	_	2	punct	_
5	a	a	DT	_	7	det	_
6	biopharmaceutical	biopharmaceutical	JJ	_	7	amod	_
7	company	company	NN	_	2	appos	8:A1=LOC
8	developing	develop	VBG	pb=develop.01	7	partmod	_
9	first	#ord#	RB	_	8	advmod	8:AM-TMP
10	in	in	IN	_	8	prep	8:AM-LOC
11	class	class	NN	_	15	nn	_
12	collagenase	collagenase	NN	p2=RB	14	hmod	_
13	-	-	HYPH	_	14	hyph	_
14	based	base	VBN	_	15	amod	_
15	products	product	NNS	_	10	pobj	16:A1=PPT
16	marketed	market	VBN	p2=VBD|pb=market.01	15	partmod	_
17	as	as	IN	_	16	prep	16:A3=PRD
18	XIAFLEX®	xiaflex®	NNP	_	17	pobj	_
19	(	(	-LRB-	_	22	punct	_
20	collagenase	collagenase	NN	p2=VBP	22	nn	_
21	clostridium	clostridium	NN	p2=JJ	22	nn	_
22	histolyticum	histolyticum	NN	p2=RB	18	appos	_
23	or	or	CC	_	22	cc	_
24	CCH	cch	NNP	p2=NN	22	conj	_
25	)	)	-RRB-	_	24	punct	_
26	in	in	IN	_	16	prep	16:AM-LOC
27	the	the	DT	_	28	det	_
28	U.S.	u.s.	NNP	_	26	pobj	_
29	and	and	CC	_	28	cc	_
30	XIAPEX®	xiapex®	NNP	_	28	conj	_
31	in	in	IN	_	36	prep	36:AM-LOC
32	the	the	DT	_	33	det	_
33	EU	eu	NNP	_	31	pobj	_
34	,	,	,	_	36	punct	_
35	today	today	NN	_	36	npadvmod	36:AM-TMP
36	announced	announce	VBD	pb=announce.01	0	root	_
37	that	that	IN	_	55	complm	_
38	new	new	JJ	_	39	amod	_
39	analyses	analysis	NNS	_	55	nsubjpass	55:A1=PPT
40	of	of	IN	_	39	prep	_
41	data	datum	NNS	_	40	pobj	42:A0=PAG
42	evaluating	evaluate	VBG	pb=evaluate.01	41	partmod	_
43	the	the	DT	_	44	det	_
44	use	use	NN	_	42	dobj	42:A1=PPT
45	of	of	IN	_	44	prep	_
46	XIAFLEX	xiaflex	NNP	_	45	pobj	_
47	in	in	IN	_	44	prep	_
48	adult	adult	NN	_	49	nn	_
49	men	man	NNS	_	47	pobj	_
50	with	with	IN	_	49	prep	_
51	Peyronie	peyronie	NNP	_	53	poss	_
52	's	's	POS	_	51	possessive	_
53	disease	disease	NN	_	50	pobj	_
54	were	be	VBD	_	55	auxpass	_
55	presented	present	VBN	pb=present.01	36	ccomp	36:A1=PPT
56	by	by	IN	_	55	agent	55:A0=PAG
57	BioSpecifics	biospecifics	NNP	p2=NNS	59	poss	_
58	'	'	POS	p2=''	57	possessive	_
59	partner	partner	NN	_	56	pobj	_
60	,	,	,	_	59	punct	_
61	Auxilium	auxilium	NNP	_	62	nn	_
62	Pharmaceuticals	pharmaceuticals	NNP	p2=NNPS	64	nn	_
63	,	,	,	_	64	punct	_
64	Inc	inc	NNP	_	59	appos	_
65	.	.	.	_	36	punct	_

1	(	(	-LRB-	_	2	punct	_
2	Auxilium	auxilium	NN	p2=NNP	0	root	_
3	)	)	-RRB-	_	2	punct	_
4	at	at	IN	_	2	prep	_
5	the	the	DT	_	8	det	_
6	2014	0	CD	p2=NNP	8	num	_
7	Annual	annual	NNP	_	8	nn	_
8	Meeting	meeting	NNP	_	4	pobj	18:A1=PPT
9	of	of	IN	_	8	prep	_
10	the	the	DT	_	13	det	_
11	American	american	NNP	p2=JJ	13	nn	_
12	Urological	urological	NNP	_	13	nn	_
13	Association	association	NNP	_	9	pobj	_
14	(	(	-LRB-	_	15	punct	_
15	AUA	aua	NNP	_	13	appos	_
16	)	)	-RRB-	_	15	punct	_
17	being	be	VBG	_	18	auxpass	_
18	held	hold	VBN	pb=hold.04	8	partmod	_
19	in	in	IN	_	18	prep	18:AM-LOC
20	Orlando	orlando	NNP	_	19	pobj	_
21	,	,	,	_	20	punct	_
22	Florida	florida	NNP	_	20	appos	_
23	on	on	IN	_	18	prep	18:AM-TMP
24	May	may	NNP	_	23	pobj	_
25	16-21	0	CD	_	24	num	_
26	,	,	,	_	24	punct	_
27	2014	0	CD	_	24	num	_
28	.	.	.	_	2	punct	_

1	"	"	``	p2=''	8	punct	_
2	The	the	DT	_	4	det	_
3	new	new	JJ	_	4	amod	_
4	data	datum	NNS	p2=NN	8	nsubj	8:A0=PAG;5:A1=PPT
5	presented	present	VBN	p2=VBD|pb=present.01	4	partmod	_
6	at	at	IN	_	5	prep	5:AM-LOC
7	AUA	aua	NNP	_	6	pobj	_
8	highlight	highlight	VB	p2=VBP|pb=highlight.01	0	root	_
9	the	the	DT	_	10	det	_
10	benefit	benefit	NN	_	8	dobj	8:A1=PPT
11	,	,	,	_	10	punct	_
12	safety	safety	NN	_	10	conj	_
13	and	and	CC	_	12	cc	_
14	ease	ease	NN	p2=NNS	12	conj	_
15	of	of	IN	_	10	prep	_
16	use	use	NN	_	15	pobj	_
17	of	of	IN	_	16	prep	_
18	XIAFLEX	xiaflex	NNP	_	17	pobj	_
19	in	in	IN	_	16	prep	_
20	this	this	DT	_	22	det	_
21	patient	patient	JJ	_	22	amod	_
22	population	population	NN	_	19	pobj	_
23	as	as	RB	_	25	advmod	_
24	well	well	RB	_	25	advmod	_
25	as	as	IN	_	22	cc	_
26	elaborate	elaborate	NN	p2=JJ	22	conj	_
27	on	on	IN	_	26	prep	_
28	physician	physician	NN	p2=JJ	29	nn	_
29	training	training	NN	_	27	pobj	32:A0
30	that	that	WDT	_	32	nsubj	32:R-A0
31	may	may	MD	_	32	aux	32:AM-MOD
32	increase	increase	VB	pb=increase.01	29	rcmod	_
33	urologists	urologist	NNS	p2=VBZ	35	poss	_
34	'	'	POS	_	33	possessive	_
35	familiarity	familiarity	NN	_	32	dobj	32:A1=PPT
36	with	with	IN	_	35	prep	_
37	XIAFLEX	xiaflex	NNP	_	36	pobj	_
38	and	and	CC	_	35	cc	_
39	the	the	DT	_	41	det	_
40	injection	injection	NN	_	41	nn	_
41	technique	technique	NN	_	35	conj	_
42	.	.	.	_	8	punct	_

1	We	we	PRP	_	2	nsubj	2:A0=PAG
2	feel	feel	VBP	pb=feel.02	15	ccomp	15:A1=PPT
3	these	these	DT	_	4	det	_
4	analyses	analysis	NNS	_	6	nsubj	6:A0
5	further	far	JJ	p2=RB	6	advmod	_
6	support	support	VB	pb=support.01	2	ccomp	2:A1=PPT
7	the	the	DT	_	9	det	_
8	commercial	commercial	JJ	_	9	amod	_
9	potential	potential	NN	_	6	dobj	6:A1
10	of	of	IN	_	9	prep	_
11	this	this	DT	_	12	det	_
12	product	product	NN	_	10	pobj	_
13	,	,	,	_	15	punct	_
14	"	"	''	_	15	punct	_
15	said	say	VBD	pb=say.01	0	root	_
16	Thomas	thomas	NNP	_	18	nn	_
17	L.	l.	NNP	_	18	nn	_
18	Wegman	wegman	NNP	_	15	nsubj	15:A0
19	,	,	,	_	18	punct	_
20	President	president	NNP	_	18	appos	_
21	of	of	IN	_	20	prep	_
22	BioSpecifics	biospecifics	NNP	_	21	pobj	_
23	.	.	.	_	15	punct	_

1	"	"	``	_	3	punct	_
2	We	we	PRP	_	3	nsubj	3:A1=PPT
3	are	be	VBP	pb=be.01	0	root	_
4	very	very	RB	_	5	advmod	_
5	optimistic	optimistic	JJ	_	3	acomp	3:A2=PRD
6	about	about	IN	_	5	prep	_
7	the	the	DT	_	9	det	_
8	market	market	NN	_	9	nn	_
9	potential	potential	NN	p2=JJ	6	pobj	_
10	of	of	IN	_	9	prep	_
11	XIAFLEX	xiaflex	NNP	_	10	pobj	_
12	for	for	IN	_	9	prep	_
13	Peyronie	peyronie	NNP	_	15	poss	_
14	's	's	POS	_	13	possessive	_
15	disease	disease	NN	_	12	pobj	_
16	,	,	,	_	3	punct	_
17	particularly	particularly	RB	_	18	advmod	_
18	based	base	VBN	_	3	prep	3:AM-ADV
19	on	on	IN	_	18	prep	_
20	numbers	number	NNS	_	19	pobj	22:A1
21	we	we	PRP	_	22	nsubj	22:A0=PAG
22	reported	report	VBD	pb=report.01	20	rcmod	_
23	from	from	IN	_	22	prep	22:AM-TMP
24	the	the	DT	_	26	det	_
25	first	#ord#	JJ	_	26	amod	_
26	quarter	quarter	NN	_	23	pobj	_
27	of	of	IN	_	26	prep	_
28	2014	0	CD	_	27	pobj	_
29	of	of	IN	_	28	prep	_
30	vials	vial	NNS	_	29	pobj	31:A1=PPT
31	shipped	ship	VBN	pb=ship.01	30	partmod	_
32	and	and	CC	_	31	cc	_
33	the	the	DT	_	35	det	_
34	impressive	impressive	JJ	_	35	amod	_
35	growth	growth	NN	_	15	appos	36:A1
36	seen	see	VBN	pb=see.01	35	partmod	_
37	in	in	IN	_	36	prep	36:AM-TMP
38	the	the	DT	_	39	det	_
39	month	month	NN	_	37	pobj	_
40	of	of	IN	_	39	prep	_
41	April	april	NNP	_	40	pobj	_
42	.	.	.	_	3	punct	_

1	We	we	PRP	_	2	nsubj	2:A0
2	hope	hope	VBP	pb=hope.01	0	root	_
3	this	this	DT	_	4	det	_
4	momentum	momentum	NN	_	5	nsubj	5:A1=PPT
5	continues	continue	VBZ	pb=continue.01	2	ccomp	2:A1=PPT
6	as	as	IN	_	10	mark	_
7	physicians	physician	NNS	_	10	nsubj	10:A1=PPT
8	and	and	CC	_	7	cc	_
9	patients	patient	NNS	_	7	conj	_
10	become	become	VBP	p2=VB|pb=become.01	5	advcl	5:AM-TMP
11	more	more	RBR	_	12	advmod	_
12	comfortable	comfortable	JJ	_	10	acomp	10:A2=PRD
13	with	with	IN	_	12	prep	_
14	the	the	DT	_	15	det	_
15	procedure	procedure	NN	_	13	pobj	_
16	and	and	CC	_	15	cc	_
17	product	product	NN	_	18	nn	_
18	profile	profile	NN	_	15	conj	_
19	.	.	.	_	2	punct	_
20	"	"	''	_	2	punct	_

1	XIAFLEX	xiaflex	NNP	_	3	nsubjpass	3:A1=PPT
2	was	be	VBD	_	3	auxpass	_
3	approved	approve	VBN	pb=approve.01	0	root	_
4	by	by	IN	_	3	agent	3:A0
5	the	the	DT	_	10	det	_
6	U.S.	u.s.	NNP	_	10	nn	_
7	Food	food	NNP	_	10	nn	_
8	&	&	CC	_	7	cc	_
9	Drug	drug	NNP	_	7	conj	_
10	Administration	administration	NNP	_	4	pobj	_
11	(	(	-LRB-	_	12	punct	_
12	FDA	fda	NNP	_	10	appos	_
13	)	)	-RRB-	_	12	punct	_
14	in	in	IN	_	3	prep	3:AM-TMP
15	December	december	NNP	_	14	pobj	_
16	2013	0	CD	_	15	num	_
17	for	for	IN	_	3	prep	_
18	the	the	DT	_	19	det	_
19	treatment	treatment	NN	_	17	pobj	_
20	of	of	IN	_	19	prep	_
21	Peyronie	peyronie	NNP	_	23	poss	_
22	's	's	POS	_	21	possessive	_
23	disease	disease	NN	_	20	pobj	_
24	in	in	IN	_	19	prep	_
25	men	man	NNS	_	24	pobj	_
26	with	with	IN	_	19	prep	_
27	a	a	DT	_	29	det	_
28	palpable	palpable	JJ	_	29	amod	_
29	plaque	plaque	NN	_	26	pobj	_
30	and	and	CC	_	29	cc	_
31	a	a	DT	_	32	det	_
32	curvature	curvature	NN	_	29	conj	_
33	of	of	IN	_	32	prep	_
34	30	0	CD	_	35	num	_
35	degrees	degree	NNS	_	33	pobj	_
36	or	or	CC	_	35	cc	_
37	greater	great	JJR	_	35	conj	_
38	at	at	IN	_	32	prep	_
39	the	the	DT	_	40	det	_
40	start	start	NN	_	38	pobj	_
41	of	of	IN	_	40	prep	_
42	therapy	therapy	NN	_	41	pobj	_
43	.	.	.	_	3	punct	_

1	The	the	DT	_	2	det	_
2	product	product	NN	_	3	nsubj	3:A1=PPT
3	became	become	VBD	pb=become.01	0	root	_
4	commercially	commercially	RB	_	5	advmod	_
5	available	available	JJ	_	3	acomp	3:A2=PRD
6	in	in	IN	_	3	prep	3:AM-TMP
7	January	january	NNP	_	6	pobj	_
8	2014	0	CD	_	7	num	_
9	.	.	.	_	3	punct	_

1	XIAFLEX	xiaflex	NNP	p2=NN	4	nsubjpass	4:A1=PPT
2	was	be	VBD	_	4	auxpass	_
3	already	already	RB	_	4	advmod	4:AM-TMP
4	approved	approve	VBN	pb=approve.01	0	root	_
5	in	in	IN	_	4	prep	4:AM-LOC
6	the	the	DT	_	7	det	_
7	U.S.	u.s.	NNP	_	5	pobj	_
8	,	,	,	_	7	punct	_
9	EU	eu	NNP	_	7	conj	_
10	,	,	,	_	9	punct	_
11	Canada	canada	NNP	_	9	conj	_
12	and	and	CC	_	11	cc	_
13	Australia	australia	NNP	_	11	conj	_
14	for	for	IN	_	4	prep	4:AM-TMP
15	the	the	DT	_	16	det	_
16	treatment	treatment	NN	_	14	pobj	_
17	of	of	IN	_	16	prep	_
18	adult	adult	NN	_	19	nn	_
19	Dupuytren	dupuytren	NNP	p2=NNPS	22	poss	_
20	's	's	POS	_	19	possessive	_
21	contracture	contracture	JJ	p2=NN	22	amod	_
22	patients	patient	NNS	_	17	pobj	_
23	with	with	IN	_	16	prep	_
24	a	a	DT	_	26	det	_
25	palpable	palpable	JJ	_	26	amod	_
26	cord	cord	NN	_	23	pobj	_
27	in	in	IN	_	26	prep	_
28	the	the	DT	_	29	det	_
29	palm	palm	NN	_	27	pobj	_
30	.	.	.	_	4	punct	_

1	75	0	CD	_	2	num	_
2	percent	percent	NN	_	9	nsubj	9:A1=PPT
3	of	of	IN	_	2	prep	_
4	men	man	NNS	_	3	pobj	_
5	with	with	IN	_	4	prep	_
6	Peyronie	peyronie	NNP	_	8	poss	_
7	's	's	POS	_	6	possessive	_
8	disease	disease	NN	_	5	pobj	_
9	treated	treat	VBD	p2=VBN|pb=treat.01	17	ccomp	_
10	with	with	IN	_	9	prep	9:A2=PRD
11	XIAFLEX	xiaflex	NNP	_	10	pobj	_
12	in	in	IN	_	9	prep	9:AM-LOC
13	the	the	DT	_	16	det	_
14	IMPRESS	impress	NNP	p2=JJ	16	nn	_
15	pivotal	pivotal	JJ	_	16	amod	_
16	studies	study	NNS	_	12	pobj	_
17	had	have	VBD	pb=have.03	0	root	_
18	a	a	DT	_	21	det	_
19	clinically	clinically	RB	_	20	advmod	_
20	meaningful	meaningful	JJ	_	21	amod	_
21	improvement	improvement	NN	_	17	dobj	17:A1=PPT
22	in	in	IN	_	21	prep	_
23	their	their	PRP$	_	26	poss	_
24	penile	penile	NN	p2=NNS	25	nn	_
25	curvature	curvature	NN	p2=VBP	26	nn	_
26	deformity	deformity	NN	_	22	pobj	_
27	by	by	IN	_	17	prep	17:AM-TMP
28	the	the	DT	_	29	det	_
29	end	end	NN	_	27	pobj	_
30	of	of	IN	_	29	prep	_
31	the	the	DT	_	32	det	_
32	trials	trial	NNS	_	30	pobj	_
33	.	.	.	_	17	punct	_

1	These	these	DT	_	2	det	_
2	subjects	subject	NNS	_	3	nsubj	3:A0=PAG
3	reported	report	VBD	pb=report.01	0	root	_
4	an	an	DT	_	5	det	_
5	improvement	improvement	NN	_	3	dobj	3:A1
6	of	of	IN	_	5	prep	_
7	25	0	CD	_	8	num	_
8	percent	percent	NN	_	6	pobj	_
9	or	or	CC	_	5	cc	_
10	greater	great	JJR	_	5	conj	_
11	in	in	IN	_	5	prep	_
12	penile	penile	NN	p2=NNS	13	nn	_
13	curvature	curvature	NN	p2=VBP	14	nn	_
14	deformity	deformity	NN	_	11	pobj	_
15	.	.	.	_	3	punct	_

1	An	an	DT	_	3	det	_
2	injection	injection	NN	_	3	nn	_
3	simulator	simulator	NN	_	11	nsubjpass	4:A0=PAG;11:A1=PRD
4	using	use	VBG	pb=use.01	3	partmod	_
5	a	a	DT	_	8	det	_
6	"	"	``	_	8	punct	_
7	smart	smart	JJ	_	8	amod	_
8	syringe	syringe	NN	_	4	dobj	4:A1=PPT
9	"	"	''	_	8	punct	_
10	was	be	VBD	_	11	auxpass	_
11	developed	develop	VBN	pb=develop.02	0	root	_
12	to	to	TO	_	13	aux	_
13	provide	provide	VB	pb=provide.01	11	advcl	_
14	clinicians	clinician	NNS	p2=NNPS	13	iobj	18:A0=PAG;13:A2=GOL
15	an	an	DT	_	16	det	_
16	opportunity	opportunity	NN	_	13	dobj	13:A1=PPT
17	to	to	TO	_	18	aux	_
18	practice	practice	VB	pb=practice.01	16	infmod	_
19	the	the	DT	_	22	det	_
20	XIAFLEX	xiaflex	NNP	_	22	nn	_
21	injection	injection	NN	_	22	nn	_
22	technique	technique	NN	_	18	dobj	18:A1=PPT
23	.	.	.	_	11	punct	_

1	Use	use	NN	p2=VB	10	nsubj	10:A0=PAG
2	of	of	IN	_	1	prep	_
3	such	such	PDT	_	5	amod	_
4	a	a	DT	_	5	det	_
5	model	model	NN	_	2	pobj	_
6	in	in	IN	_	5	prep	_
7	physician	physician	NN	p2=JJ	8	nn	_
8	training	training	NN	_	6	pobj	_
9	may	may	MD	_	10	aux	10:AM-MOD
10	increase	increase	VB	pb=increase.01	0	root	_
11	urologists	urologist	NNS	p2=RP	13	poss	_
12	'	'	POS	_	11	possessive	_
13	familiarity	familiarity	NN	_	10	dobj	10:A1=PPT
14	with	with	IN	_	13	prep	_
15	the	the	DT	_	17	det	_
16	injection	injection	NN	_	17	nn	_
17	technique	technique	NN	_	14	pobj	_
18	for	for	IN	_	17	prep	_
19	XIAFLEX	xiaflex	NNP	_	20	nn	_
20	treatment	treatment	NN	_	18	pobj	_
21	of	of	IN	_	20	prep	_
22	Peyronie	peyronie	NNP	_	24	poss	_
23	's	's	POS	_	22	possessive	_
24	disease	disease	NN	_	21	pobj	_
25	by	by	IN	_	10	prep	10:AM-MNR
26	providing	provide	VBG	pb=provide.01	25	pcomp	_
27	both	both	CC	p2=DT	28	preconj	_
28	visual	visual	JJ	_	31	amod	_
29	and	and	CC	_	28	cc	_
30	tactile	tactile	JJ	_	28	conj	_
31	feedback	feedback	NN	_	26	dobj	26:A1=PPT
32	during	during	IN	_	26	prep	26:AM-TMP
33	simulated	simulated	JJ	p2=VBN	34	nn	_
34	injection	injection	NN	_	32	pobj	_
35	.	.	.	_	10	punct	_

1	The	the	DT	_	2	det	_
2	administration	administration	NN	_	24	nsubj	24:A0=PAG
3	of	of	IN	_	2	prep	_
4	a	a	DT	_	7	det	_
5	second	#ord#	JJ	p2=NN	7	amod	_
6	XIAFLEX	xiaflex	NNP	_	7	nn	_
7	injection	injection	NN	_	3	pobj	_
8	1	0	CD	_	7	num	_
9	,	,	,	_	7	punct	_
10	2	0	CD	_	13	num	_
11	or	or	CC	_	10	cc	_
12	3	0	CD	_	10	conj	_
13	days	day	NNS	_	14	npadvmod	_
14	after	after	IN	p2=RB	7	prep	_
15	the	the	DT	_	17	det	_
16	first	#ord#	JJ	_	17	amod	_
17	injection	injection	NN	_	14	pobj	_
18	during	during	IN	_	17	prep	_
19	Treatment	treatment	NNP	p2=NN	20	nn	_
20	Cycle	cycle	NNP	p2=NN	18	pobj	_
21	1	0	CD	_	20	num	_
22	did	do	VBD	_	24	aux	_
23	not	not	RB	_	24	neg	24:AM-NEG
24	impact	impact	VB	pb=impact.01	0	root	_
25	the	the	DT	_	26	det	_
26	safety	safety	NN	_	24	dobj	24:A1=PPT
27	or	or	CC	_	26	cc	_
28	effectiveness	effectiveness	NN	_	26	conj	_
29	of	of	IN	_	26	prep	_
30	XIAFLEX	xiaflex	NNP	_	29	pobj	_
31	in	in	IN	_	26	prep	_
32	the	the	DT	_	33	det	_
33	treatment	treatment	NN	_	31	pobj	_
34	of	of	IN	_	33	prep	_
35	Peyronie	peyronie	NNP	_	38	poss	_
36	's	's	POS	_	35	possessive	_
37	curvature	curvature	NN	p2=JJ	38	nn	_
38	deformity	deformity	NN	_	34	pobj	39:A1=PPT
39	evaluated	evaluate	VBN	p2=VBD|pb=evaluate.01	38	partmod	_
40	at	at	IN	_	39	prep	39:AM-TMP
41	Week	week	NNP	_	40	pobj	_
42	6	0	CD	_	41	num	_
43	.	.	.	_	24	punct	_

1	The	the	DT	_	2	det	_
2	improvement	improvement	NN	_	9	nsubj	9:A1=PPT
3	in	in	IN	_	2	prep	_
4	curvature	curvature	NN	p2=JJ	5	nn	_
5	deformity	deformity	NN	_	8	nn	_
6	and	and	CC	_	5	cc	_
7	safety	safety	NN	_	5	conj	_
8	measurements	measurement	NNS	_	3	pobj	_
9	were	be	VBD	pb=be.01	0	root	_
10	comparable	comparable	JJ	_	9	acomp	9:A2=PRD
11	regardless	regardless	RB	_	9	advmod	9:AM-ADV
12	of	of	IN	_	11	prep	_
13	when	when	WRB	_	18	advmod	18:R-AM-TMP
14	the	the	DT	_	16	det	_
15	second	#ord#	JJ	_	16	amod	_
16	injection	injection	NN	_	18	nsubjpass	18:A1=PPT
17	was	be	VBD	_	18	auxpass	_
18	administered	administer	VBN	pb=administer.01	12	pcomp	_
19	during	during	IN	_	18	prep	18:AM-TMP
20	the	the	DT	_	23	det	_
21	first	#ord#	JJ	_	23	amod	_
22	treatment	treatment	NN	_	23	nn	_
23	cycle	cycle	NN	_	19	pobj	_
24	.	.	.	_	9	punct	_

1	These	these	DT	_	2	det	_
2	data	datum	NNS	p2=NN	3	nsubj	3:A0
3	support	support	VBP	p2=NN|pb=support.01	0	root	_
4	flexibility	flexibility	NN	_	3	dobj	3:A1
5	in	in	IN	_	4	prep	_
6	planning	plan	VBG	p2=NN|pb=plan.01	5	pcomp	_
7	XIAFLEX	xiaflex	NNP	_	9	nn	_
8	treatment	treatment	NN	_	9	nn	_
9	cycles	cycle	NNS	_	6	dobj	6:A1=PPT
10	.	.	.	_	3	punct	_

1	About	about	RB	p2=IN	4	advmod	_
2	BioSpecifics	biospecifics	NNP	p2=NNPS	4	nn	_
3	Technologies	technology	NNPS	p2=NNP	4	nn	_
4	Corp	corp	NNP	_	0	root	_
5	.	.	.	_	4	punct	_

1	BioSpecifics	biospecifics	NNP	p2=NNS	3	nn	_
2	Technologies	technology	NNPS	p2=NNP	3	nn	_
3	Corp	corp	NNP	_	0	root	_
4	.	.	.	_	3	punct	_

1	is	be	VBZ	pb=be.01	0	root	_
2	a	a	DT	_	4	det	_
3	biopharmaceutical	biopharmaceutical	JJ	_	4	amod	_
4	company	company	NN	_	1	attr	7:A0=PAG;1:A2=PRD
5	that	that	WDT	_	7	nsubj	7:R-A0
6	has	have	VBZ	_	7	aux	_
7	developed	develop	VBN	pb=develop.02	4	rcmod	_
8	injectable	injectable	JJ	_	9	amod	_
9	collagenase	collagenase	NN	p2=NNS	7	dobj	7:A1=PRD
10	for	for	IN	_	7	prep	_
11	twelve	#crd#	CD	p2=JJ	13	num	_
12	clinical	clinical	JJ	_	13	amod	_
13	indications	indication	NNS	_	10	pobj	_
14	to	to	IN	_	13	prep	_
15	date	date	NN	_	14	pobj	_
16	.	.	.	_	1	punct	_

1	Injectable	injectable	JJ	p2=NNP	2	amod	_
2	collagenase	collagenase	NN	_	4	nsubjpass	4:A1=PPT
3	is	be	VBZ	_	4	auxpass	_
4	approved	approve	VBN	pb=approve.01	0	root	_
5	for	for	IN	_	4	prep	4:A2=PRD
6	marketing	marketing	NN	_	5	pobj	_
7	as	as	IN	_	1	prep	_
8	XIAFLEX® 	xiaflex® 	NNP	_	12	nn	_
9	(	(	-LRB-	_	12	punct	_
10	collagenase	collagenase	NN	p2=VBP	12	nn	_
11	clostridium	clostridium	NN	p2=JJ	12	nn	_
12	histolyticum	histolyticum	NN	p2=RB	7	pobj	_
13	or	or	CC	_	12	cc	_
14	CCH	cch	NNP	p2=NN	12	conj	_
15	)	)	-RRB-	_	14	punct	_
16	in	in	IN	_	7	prep	_
17	the	the	DT	_	18	det	_
18	U.S.	u.s.	NNP	_	16	pobj	_
19	for	for	IN	_	12	prep	_
20	the	the	DT	_	21	det	_
21	treatment	treatment	NN	_	19	pobj	_
22	of	of	IN	_	21	prep	_
23	adult	adult	NN	_	24	nn	_
24	Dupuytren	dupuytren	NNP	p2=NNPS	27	poss	_
25	's	's	POS	_	24	possessive	_
26	contracture	contracture	JJ	p2=NN	27	amod	_
27	patients	patient	NNS	_	22	pobj	_
28	with	with	IN	_	21	prep	_
29	a	a	DT	_	31	det	_
30	palpable	palpable	JJ	_	31	amod	_
31	cord	cord	NN	_	28	pobj	_
32	in	in	IN	_	31	prep	_
33	the	the	DT	_	34	det	_
34	palm	palm	NN	_	32	pobj	_
35	and	and	CC	_	19	cc	_
36	for	for	IN	_	19	conj	_
37	Peyronie	peyronie	NNP	_	39	poss	_
38	's	's	POS	_	37	possessive	_
39	disease	disease	NN	_	36	pobj	_
40	in	in	IN	_	39	prep	_
41	men	man	NNS	_	40	pobj	_
42	with	with	IN	_	12	prep	_
43	a	a	DT	_	45	det	_
44	palpable	palpable	JJ	_	45	amod	_
45	plaque	plaque	NN	_	42	pobj	_
46	and	and	CC	_	45	cc	_
47	a	a	DT	_	49	det	_
48	curvature	curvature	NN	p2=JJ	49	nn	_
49	deformity	deformity	NN	_	45	conj	_
50	of	of	IN	_	49	prep	_
51	30	0	CD	_	52	num	_
52	degrees	degree	NNS	_	50	pobj	_
53	or	or	CC	_	49	cc	_
54	greater	great	JJR	_	49	conj	_
55	at	at	IN	_	54	prep	_
56	the	the	DT	_	57	det	_
57	start	start	NN	_	55	pobj	_
58	of	of	IN	_	57	prep	_
59	therapy	therapy	NN	_	58	pobj	_
60	by	by	IN	_	57	prep	_
61	BioSpecifics	biospecifics	NNP	p2=NNS	63	poss	_
62	'	'	POS	p2=''	61	possessive	_
63	partner	partner	NN	_	60	pobj	_
64	,	,	,	_	63	punct	_
65	Auxilium	auxilium	NNP	_	66	nn	_
66	Pharmaceuticals	pharmaceuticals	NNP	p2=NNPS	68	nn	_
67	,	,	,	_	68	punct	_
68	Inc	inc	NNP	_	63	appos	_
69	.	.	.	_	4	punct	_

1	(	(	-LRB-	_	2	punct	_
2	Auxilium	auxilium	NNP	p2=UH	0	root	_
3	)	)	-RRB-	_	2	punct	_
4	.	.	.	_	2	punct	_

1	Auxilium	auxilium	NN	p2=NNP	3	nsubjpass	3:A1=COM
2	is	be	VBZ	_	3	auxpass	_
3	partnered	partner	VBN	p2=JJ|pb=partner.01	0	root	_
4	with	with	IN	_	3	prep	3:AM-COM
5	Actelion	actelion	NNP	_	7	nn	_
6	Pharmaceuticals	pharmaceuticals	NNP	p2=NNPS	7	nn	_
7	Ltd.	ltd.	NNP	_	4	pobj	_
8	for	for	IN	_	3	prep	_
9	the	the	DT	_	10	det	_
10	marketing	marketing	NN	_	8	pobj	_
11	of	of	IN	_	10	prep	_
12	XIAFLEX	xiaflex	NNP	_	14	nn	_
13	in Canada and	in canada and	NNP	_	14	nn	_
14	Australia	australia	NNP	_	11	pobj	_
15	,	,	,	_	10	punct	_
16	and	and	CC	_	10	cc	_
17	Swedish	swedish	JJ	p2=NNP	20	nn	_
18	Orphan	orphan	NNP	_	20	nn	_
19	Biovitrium	biovitrium	NNP	p2=NN	20	nn	_
20	AB	ab	NNP	_	10	conj	_
21	for	for	IN	_	3	prep	_
22	the	the	DT	_	23	det	_
23	marketing	marketing	NN	_	21	pobj	_
24	of	of	IN	_	23	prep	_
25	XIAPEX® 	xiapex® 	NNP	_	24	pobj	_
26	(	(	-LRB-	_	25	punct	_
27	the	the	DT	_	29	det	_
28	EU	eu	NNP	_	29	nn	_
29	tradename	tradename	NN	p2=VBD	25	appos	_
30	for	for	IN	_	29	prep	_
31	CCH	cch	NNP	p2=NN	30	pobj	_
32	)	)	-RRB-	_	25	punct	_
33	in	in	IN	_	3	prep	_
34	71	0	CD	_	38	num	_
35	Eurasian	eurasian	JJ	p2=NNP	38	amod	_
36	and	and	CC	_	35	cc	_
37	African	african	JJ	_	35	conj	_
38	countries	country	NNS	_	33	pobj	_
39	for	for	IN	_	3	prep	_
40	the	the	DT	_	41	det	_
41	treatment	treatment	NN	_	39	pobj	_
42	of	of	IN	_	41	prep	_
43	Dupuytren	dupuytren	NNP	_	45	poss	_
44	's	's	POS	_	43	possessive	_
45	contracture	contracture	NN	_	42	pobj	_
46	,	,	,	_	3	punct	_
47	and	and	CC	_	3	cc	_
48	Peyronie	peyronie	NNP	_	50	poss	_
49	's	's	POS	_	48	possessive	_
50	disease	disease	NN	_	7	appos	_
51	pending	pending	VBG	_	50	partmod	_
52	applicable	applicable	JJ	_	54	amod	_
53	regulatory	regulatory	JJ	_	54	amod	_
54	approvals	approval	NNS	_	51	dobj	_
55	.	.	.	_	3	punct	_

1	CCH	cch	NNP	p2=NN	2	nsubj	2:A1=PPT
2	is	be	VBZ	pb=be.01	0	root	_
3	in	in	IN	_	2	prep	2:A2=PRD
4	clinical	clinical	JJ	_	5	amod	_
5	development	development	NN	_	3	pobj	_
6	for	for	IN	_	5	prep	_
7	the	the	DT	_	8	det	_
8	treatment	treatment	NN	_	6	pobj	_
9	of	of	IN	_	8	prep	_
10	several	several	JJ	_	13	amod	_
11	additional	additional	JJ	_	13	amod	_
12	promising	promising	JJ	p2=VBG	13	amod	_
13	indications	indication	NNS	_	9	pobj	_
14	.	.	.	_	2	punct	_

1	Auxilium	auxilium	NN	p2=NNP	3	nsubj	3:A0=PAG
2	is	be	VBZ	_	3	aux	_
3	testing	test	VBG	p2=NN|pb=test.01	0	root	_
4	CCH	cch	NNP	p2=NN	3	dobj	3:A1=LOC
5	for	for	IN	_	3	prep	_
6	frozen	frozen	JJ	p2=VBN	7	amod	_
7	shoulder	shoulder	NN	_	8	nn	_
8	syndrome	syndrome	NN	_	5	pobj	_
9	in	in	IN	_	3	prep	3:AM-LOC
10	a	a	DT	_	13	det	_
11	Phase	phase	NN	p2=NNP	13	nn	_
12	2b	0b	CD	p2=JJ	13	nn	_
13	study	study	NN	_	9	pobj	_
14	and	and	CC	_	13	cc	_
15	also	also	RB	_	16	advmod	_
16	for	for	IN	_	3	prep	_
17	cellulite	cellulite	NN	p2=NNS	16	pobj	_
18	in	in	IN	_	17	prep	_
19	a	a	DT	_	22	det	_
20	Phase	phase	NN	p2=NNP	22	nn	_
21	2a	0a	CD	p2=NN	22	num	_
22	study	study	NN	_	18	pobj	_
23	.	.	.	_	3	punct	_

1	BioSpecifics	biospecifics	NNP	p2=NNS	4	nsubj	4:A0=PAG
2	is	be	VBZ	_	4	aux	_
3	currently	currently	RB	_	4	advmod	4:AM-TMP
4	managing	manage	VBG	pb=manage.01	0	root	_
5	the	the	DT	_	6	det	_
6	development	development	NN	_	4	dobj	4:A1=PPT
7	of	of	IN	_	6	prep	_
8	CCH	cch	NNP	_	7	pobj	_
9	for	for	IN	_	4	prep	4:AM-PRP
10	the	the	DT	_	11	det	_
11	treatment	treatment	NN	_	9	pobj	_
12	of	of	IN	_	11	prep	_
13	human	human	JJ	p2=NN	16	amod	_
14	and	and	CC	_	13	cc	_
15	canine	canine	JJ	p2=NN	13	conj	_
16	lipomas	lipoma	NNS	p2=NN	12	pobj	_
17	.	.	.	_	4	punct	_

1	For	for	IN	_	7	prep	_
2	more	more	JJR	_	3	amod	_
3	information	information	NN	_	1	pobj	_
4	,	,	,	_	7	punct	_
5	please	please	UH	p2=VB	7	intj	_
6	visit 	visit 	''	p2=VB	7	punct	_
7	www.biospecifics.com	#url#	ADD	_	0	root	_
8	.	.	.	_	7	punct	_

